secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001104659-26-019405
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q4 revenue $47.7M, GAAP net loss $2.3M; FY adj EBITDA $138M, guides FY26 >$300M
--------------------------------------------------------------------------------

- Full-year 2025 total revenue $296M, GAAP net income $24M ($0.15 diluted EPS), adjusted EBITDA $138M.
- Q4 2025 total revenue $47.7M (down 47% YoY); GAAP net loss $2.3M vs net income $2.3M in Q4 2024.
- LINZESS EUTRx demand grew 11% YoY in FY2025; over 5.7M unique patients treated since launch.
- Provides FY2026 guidance: LINZESS U.S. net sales $1.125-1.175B, total revenue $450-475M, adj EBITDA >$300M.
- Apraglutide confirmatory Phase 3 trial (STARS-2) design finalized; site initiations expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926019405/0001104659-26-019405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926019405/tm267094d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-019405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer